14 completed, 3 unknown, 1 terminated. 18 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 14, Unknown 3, Terminated 1 |
| Phase 1 | 3 | Completed 1, Terminated 1, Unknown 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
Follow Measles: new trials by email Literature Review of Measles trials Research Report on Measles
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings Licenced Measles-Rubella vaccine - Measles | Phase 2 | Unknown | University of Oxford | 450 | 2023-11-15 | 2024-10-31 |
| A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine - Measles; Mumps; Rubella; Chickenpox, Measles | Phase 2 | Completed | GlaxoSmithKline | 801 | 2022-12-14 | 2025-06-22 |
| Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial Measles Rubella Vaccine (MRV-SC), MRV-MNP, PLA-MNP - Measles, Rubella | Phase 1 / Phase 2 | Completed | Micron Biomedical, Inc | 281 | 2021-05-19 | 2023-03-29 |
| Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study) Measles-Rubella vaccine Bio Farma, MR Vaccine SII - Congenital Rubella Infection, Measles | Phase 2 / Phase 3 | Completed | PT Bio Farma | 540 | 2019-09-03 | 2019-12-04 |
| Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella Measles and Rubella vaccine, Measles, Mumps and Rubella vaccine - Rubella, Measles | Phase 2 / Phase 3 | Completed | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 432 | 2018-11-20 | 2020-08-13 |
| Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Trivivac vaccine - Immunogenicity, Reactogenicity | Phase 2 / Phase 3 | Unknown | Queen Sirikit National Institute of Child Health | 200 | 2012-09-01 | 2013-01-08 |
| Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine), GSK Biologicals' 208136, new formulation - Measles, Varicella | Phase 2 | Completed | GlaxoSmithKline | 501 | 2009-06-03 | 2019-11-15 |
| Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax® - Rubella, Mumps | Phase 2 | Completed | GlaxoSmithKline | 1259 | 2009-06-03 | 2020-01-03 |
| Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years MVA-mBN85B, Rouvax - Measles | Phase 2 | Completed | Bavarian Nordic | 90 | 2009-06-01 | 2012-07-27 |
| Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer attenuated measles vaccine - Non-Small Cell Lung Cancer, Measles | Phase 1 / Phase 2 | Unknown | Soroka University Medical Center | 15 | 2009-03-01 | 2009-01-23 |
| Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix® - Varicella, Rubella | Phase 2 | Completed | GlaxoSmithKline | 1851 | 2007-11-20 | 2018-10-09 |
| Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ MeMuRu-OKA (study vac), MMR, Varicella vacc (control) - Mumps, Rubella | Phase 2 | Completed | GlaxoSmithKline | 400 | 2006-04-01 | 2016-10-07 |
| Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ MeMuRu-OKA (study vacc), MMR, Varicella vacc (control) - Varicella, Rubella | Phase 2 | Completed | GlaxoSmithKline | 446 | 2006-03-01 | 2016-10-07 |
| Immune Responses to Two Dose Varivax +/- MMR-II MMR-II, Pro-Quad, Varivax - Measles, Mumps | Phase 1 / Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 105 | 2005-10-01 | 2010-08-27 |
| A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED) V205C, measles, mumps, and rubella virus vaccine live, Comparator: Measles, Mumps, and Rubella Virus Vaccine Live - Measles | Phase 2 | Completed | Merck Sharp & Dohme LLC | 1100 | 2004-10-01 | 2017-03-15 |
| Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED) measles, mumps, and rubella virus vaccine live, Comparator: Measles, Mumps, and Rubella Virus Vaccine Live - Measles, Mumps | Phase 2 | Completed | Merck Sharp & Dohme LLC | 1210 | 2001-12-01 | 2017-03-15 |
| ProQuad Dose Selection Study (V221-011)(COMPLETED) Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: M-M-R II, Comparator: PUVV - Measles, Mumps | Phase 2 | Completed | Merck Sharp & Dohme LLC | 1551 | 1999-04-01 | 2015-04-10 |
| A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group Attenuvax, M-M-R-II - HIV Infections, Measles | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 270 | 2021-10-28 |
Rubella (13) · Mumps (9) · Chickenpox (8) · AIDS-Related Complex (1) · Acquired Immunodeficiency Syndrome (1) · Carcinoma, Non-Small-Cell Lung (1) · HIV Infections (1) · Virus Diseases (1)
Infections (18) · Mononegavirales Infections (18) · Morbillivirus Infections (18) · Paramyxoviridae Infections (18) · RNA Virus Infections (18) · Virus Diseases (17) · Rubivirus Infections (13) · Togaviridae Infections (13) · Mouth Diseases (9) · Parotid Diseases (9) · Parotitis (9) · Rubulavirus Infections (9) · Salivary Gland Diseases (9) · Stomatognathic Diseases (9) · DNA Virus Infections (8)
Measles-Mumps-Rubella Vaccine (3) · Rubella Vaccine (3) · measles, mumps, rubella, varicella vaccine (3) · Chickenpox Vaccine (2) · Hepatitis A Vaccines (2) · Heptavalent Pneumococcal Conjugate Vaccine (2) · Measles Vaccine (1)
GlaxoSmithKline (6) · Merck Sharp & Dohme LLC (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Bavarian Nordic (1) · Micron Biomedical, Inc (1) · PT Bio Farma (1) · Queen Sirikit National Institute of Child Health (1) · Soroka University Medical Center (1) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (1) · University of Oxford (1)
United States (5) · Puerto Rico (3) · Italy (2) · Taiwan (2) · Brazil (1) · Canada (1) · Colombia (1) · France (1) · Germany (1) · Indonesia (1) · Israel (1) · Latvia (1) · Singapore (1) · South Africa (1) · Thailand (1)
Chandwani S (1) · Ed Clarke, MD (1) · Kleber G Luz, PhD (1) · Krasinski K (1)
PMID 16094218, PMID 21666159, PMID 28481690, PMID 36104719, PMID 42539769